Logo image of RVNC

REVANCE THERAPEUTICS INC (RVNC) Stock Fundamental Analysis

NASDAQ:RVNC - Nasdaq - US7613301099 - Common Stock - Currency: USD

3.65  +0.01 (+0.27%)

After market: 3.66 +0.01 (+0.27%)

Fundamental Rating

2

Taking everything into account, RVNC scores 2 out of 10 in our fundamental rating. RVNC was compared to 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of RVNC have multiple concerns. RVNC is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RVNC has reported negative net income.
In the past year RVNC has reported a negative cash flow from operations.
RVNC had negative earnings in each of the past 5 years.
RVNC had a negative operating cash flow in each of the past 5 years.
RVNC Yearly Net Income VS EBIT VS OCF VS FCFRVNC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M

1.2 Ratios

RVNC's Return On Assets of -39.96% is in line compared to the rest of the industry. RVNC outperforms 44.62% of its industry peers.
Industry RankSector Rank
ROA -39.96%
ROE N/A
ROIC N/A
ROA(3y)-60.64%
ROA(5y)-53.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RVNC Yearly ROA, ROE, ROICRVNC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K

1.3 Margins

The Gross Margin of RVNC (72.61%) is better than 79.57% of its industry peers.
RVNC's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for RVNC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 72.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.51%
GM growth 5YN/A
RVNC Yearly Profit, Operating, Gross MarginsRVNC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K -40K

More info and screens

2

2. Health

2.1 Basic Checks

RVNC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RVNC has more shares outstanding
The number of shares outstanding for RVNC has been increased compared to 5 years ago.
RVNC has a worse debt/assets ratio than last year.
RVNC Yearly Shares OutstandingRVNC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
RVNC Yearly Total Debt VS Total AssetsRVNC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

RVNC has an Altman-Z score of -6.34. This is a bad value and indicates that RVNC is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of RVNC (-6.34) is worse than 67.20% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.34
ROIC/WACCN/A
WACC8.5%
RVNC Yearly LT Debt VS Equity VS FCFRVNC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 4.12 indicates that RVNC has no problem at all paying its short term obligations.
RVNC has a Current ratio (4.12) which is in line with its industry peers.
RVNC has a Quick Ratio of 3.05. This indicates that RVNC is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of RVNC (3.05) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.12
Quick Ratio 3.05
RVNC Yearly Current Assets VS Current LiabilitesRVNC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

RVNC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 53.16%, which is quite impressive.
RVNC shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.34%.
The Revenue has been growing by 129.20% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)53.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.3%
Revenue 1Y (TTM)15.34%
Revenue growth 3Y148.24%
Revenue growth 5Y129.2%
Sales Q2Q%5.47%

3.2 Future

Based on estimates for the next years, RVNC will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.17% on average per year.
The Revenue is expected to grow by 22.31% on average over the next years. This is a very strong growth
EPS Next Y57.03%
EPS Next 2Y30.61%
EPS Next 3Y22.8%
EPS Next 5Y18.17%
Revenue Next Year12.8%
Revenue Next 2Y19.79%
Revenue Next 3Y22.43%
Revenue Next 5Y22.31%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RVNC Yearly Revenue VS EstimatesRVNC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M
RVNC Yearly EPS VS EstimatesRVNC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RVNC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RVNC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RVNC Price Earnings VS Forward Price EarningsRVNC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RVNC Per share dataRVNC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

RVNC's earnings are expected to grow with 22.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.61%
EPS Next 3Y22.8%

More info and screens

0

5. Dividend

5.1 Amount

RVNC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REVANCE THERAPEUTICS INC

NASDAQ:RVNC (2/5/2025, 8:25:21 PM)

After market: 3.66 +0.01 (+0.27%)

3.65

+0.01 (+0.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-04 2025-03-04/amc
Inst Owners72.87%
Inst Owner Change-14.62%
Ins Owners1.85%
Ins Owner Change-207.08%
Market Cap381.02M
Analysts70.67
Price Target5.25 (43.84%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.02%
Min EPS beat(2)4.62%
Max EPS beat(2)33.41%
EPS beat(4)4
Avg EPS beat(4)19.57%
Min EPS beat(4)4.62%
Max EPS beat(4)33.41%
EPS beat(8)5
Avg EPS beat(8)-1.49%
EPS beat(12)6
Avg EPS beat(12)-3.54%
EPS beat(16)10
Avg EPS beat(16)-1.96%
Revenue beat(2)0
Avg Revenue beat(2)-8.84%
Min Revenue beat(2)-14.73%
Max Revenue beat(2)-2.96%
Revenue beat(4)1
Avg Revenue beat(4)-4.4%
Min Revenue beat(4)-14.73%
Max Revenue beat(4)10.16%
Revenue beat(8)3
Avg Revenue beat(8)-2.2%
Revenue beat(12)6
Avg Revenue beat(12)-0.84%
Revenue beat(16)9
Avg Revenue beat(16)2.98%
PT rev (1m)-31.93%
PT rev (3m)-42.51%
EPS NQ rev (1m)-18.27%
EPS NQ rev (3m)-57.56%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.24%
Revenue NQ rev (1m)6.51%
Revenue NQ rev (3m)-13.71%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-7.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.54
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.93
EYN/A
EPS(NY)-1.11
Fwd EYN/A
FCF(TTM)-1.87
FCFYN/A
OCF(TTM)-1.83
OCFYN/A
SpS2.37
BVpS-1.56
TBVpS-1.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.96%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 72.61%
FCFM N/A
ROA(3y)-60.64%
ROA(5y)-53.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.51%
GM growth 5YN/A
F-Score3
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 106.69%
Cap/Sales 1.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.12
Quick Ratio 3.05
Altman-Z -6.34
F-Score3
WACC8.5%
ROIC/WACCN/A
Cap/Depr(3y)40.78%
Cap/Depr(5y)54.97%
Cap/Sales(3y)6.23%
Cap/Sales(5y)171.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.3%
EPS Next Y57.03%
EPS Next 2Y30.61%
EPS Next 3Y22.8%
EPS Next 5Y18.17%
Revenue 1Y (TTM)15.34%
Revenue growth 3Y148.24%
Revenue growth 5Y129.2%
Sales Q2Q%5.47%
Revenue Next Year12.8%
Revenue Next 2Y19.79%
Revenue Next 3Y22.43%
Revenue Next 5Y22.31%
EBIT growth 1Y31.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.87%
EBIT Next 3Y26.12%
EBIT Next 5Y20.68%
FCF growth 1Y9.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.22%
OCF growth 3YN/A
OCF growth 5YN/A